Tau蛋白表达与ER阳性乳腺癌紫杉类化疗敏感性的临床分析

目的探讨Tau蛋白表达与ER阳性乳腺癌紫杉类化疗敏感性的关系。方法采用Elivison二步法免疫组化检测乳腺癌组织Tau蛋白的表达,统计分析乳腺癌组织Tau蛋白与ER的相关性,及其与含紫杉类方案新辅助化疗疗效的关系。结果 Tau蛋白在乳腺癌组织的表达率为44%（88/200）,与ER表达呈正相关（r=0.32,P〈0.0001）。Tau蛋白阴性的乳腺癌患者,紫杉类新辅助化疗疗效、病理化疗反应分级和病理完全缓解率均高于Tau蛋白阳性组,差异有统计学意义（P=0.002、P〈0.000 1、P〈0.000 1）,且这种差异在ER阳性分层分析中也存在（P=0.008、P〈0.000 1、P〈0.000 1）,但在ER阴性的乳腺癌患者中不存在（P=1.000、0.623、0.119）。结论乳腺癌组织Tau蛋白表达与ER正相关,检测Tau蛋白表达可作为ER阳性乳腺癌患者选择紫杉类化疗药物的临床依据。

Clinical analysis of Tau protein expressions and taxane-based chemo-sensitivity of breast cancer with ER positive

Objective To investigate the relationship between tau protein expressions and taxane-based chemo-sensitivity of breast cancer with estrogen receptor(ER) positive.Methods The expression of tau protein in breast cancer was detected by elivison two-step immunohistochemical methods,and the results were analyzed with the correlation to ER expression and chemo-sensitivity of taxane.Results The expressions of tau protein in breast cancer tissues were 44%(88/200).Tau protein expression was positively correlated with ER expression(r = 0.32,P < 0.000 1).The clinical efficacy,Miller-Payne pathological reactive grade and pathologic complete response rate of taxane-containing neoadjuvant chemotherapy in tau negative patients were higher than in tau positive(P = 0.002,P < 0.000 1,P < 0.000 1).There were significant differences in ER-positive subgroups(P = 0.008,P < 0.000 1,P < 0.000 1),but no significant differences in ER-negative subgroups(P = 1.000,0.623,0.119).Conclusion Tau protein expression is positively correlated with ER expression in breast cancer.The detection of tau protein expression can be chosen as a clinical basis for taxane-containing chemotherapy in ER-positive breast cancer patients.